Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder

European Urology

Volumn 41, Issue 6, 2002, Pages 588-595

  Kreder, K ^a   Mayne, C ^b   Jonas, U ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b LEICESTER GENERAL HOSPITAL   (United Kingdom)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Efficacy; Overactive bladder; Safety; Tolerability; Tolterodine

Indexed keywords

PLACEBO; TOLTERODINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FEMALE; HEADACHE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SLOW DRUG RELEASE; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; VERTIGO; XEROPHTHALMIA; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CRESOLS; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC;

EID: 0036625042     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00177-X     Document Type: Article

References (22)

1. Wein AJ, Roberts RW. Overactive bladder survey. Evaluates the extent of symptoms in family doctor setting. Fam Urol 2000;5:7-8.
2. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how do we manage them? A population-based prevalence study. BJU Int 2001;87:760-6.
3. Versi E. on behalf of the Study Group. Screening initiative confirms widespread prevalence of overactive bladder in American adults. Int Urogynecol J 2001;12:S13.
4. Abrams P, Wein AJ. The Overactive Bladder. A Widespread and Treatable Condition. Stockholm: Erick Sparre Medical AB, 1998.
5. Andersson KE. The pharmacology of lower urinary tract smooth muscles and penile and erectile tissues. Pharmacol Rev 1993;45:253-308.
6. Yarker YE, Goa KL, Fitton A. Oxybutynin: A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability. Drugs Aging 1995;6:243-6.
7. Kelleher CJ, Cardozo LD, KhulIar V, Salvatore S. A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997; 104:988-93.
8. Echols K, Verma U, Policaro F, Medina CA. Idiopathic bladder hyperactivity and Ditropan: An efficacy and compliance issue [abstract]. Obstet Gynecol 2000;95(4 Suppl 1):S24.
9. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology 1997;50(Suppl 6A):90-6.
10. Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81:801-10.
11. Drutz H, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct 1999;10:283-9.
12. Todorova A, Vonderheid-Guth B, Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 2001;41:636-44.
13. Chancellor MB. Tolterodine: Selectivity for the bladder over effects on visual accommodation [abstract]. J Urol 2000;163:229.
14. Abrams P, Malone-Lee J, Jacquetin B, Wyndaele J, Tammela T, Jonas U, Wein A. Twelve-month treatment of overactive bladder: Efficacy and tolerability of tolterodine. Drugs Aging 2001;18:551-60.
15. Appell RA, Abrams P, Drutz HP, Van Kerrebroeck P, Millard R, Wein A. Treatment of overactive bladder: Long-term tolerability and efficacy of tolterodine. World J Urol 2001;19:141-7.
16. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck T. The effect of prescribed daily dose frequency on patient medication compliance. Arch Int Med 1990;150:1881-4.
17. Olsson B, Szamosi J. Multiple-dose pharmacokinetics of a new once-daily extended-release tolterodine formulation versus immediate-release tolterodine. Clin Pharmacokinet 2001;40:227-35.
18. Van Kerrebroeck P, Kreder K, Jonas U, Zinner N, Wein A. Tolterodine once-daily: Superior efficacy and tolerability in the treatment of overactive bladder. Urology 2001;57:414-21.
19. Stahl MMS, Ekstrom B, Sparf B, Zinner N, Wein A. Urodynamic and other effects of tolterodine: A novel antimuscarinic drug for the treatment of detrusor overactivity. Neurourol Urodyn 1995;14:647-55.
20. Jonas U, Hofner K, Madersbacher H, Homdahl T. Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, Urge incontinence, and urgency: Urodynamic evaluation. World J Urol 1997;15:144-51.
21. Larsson G, Hallen B, Nilvebrant L. Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase II efficacy and safety data. Urology 1999;53:990-8.
22. Siami P, Seidman LS, Lama D, Wein A. Speed of onset of action of extended-release tolterodine 4 mg in the treatment of overactive bladder: A prospective, multicenter, open-label study. Clin Ther 2002;24(4):616-28.